Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting

The award-winning MoveOverMS.org website and MS self™ multiple sclerosis mobile app featured at Booth #406

ARDSLEY, N.Y.--()--Acorda Therapeutics, Inc. (Nasdaq:ACOR), a biotechnology company based in New York, will provide demonstrations of its award-winning digital tools for multiple sclerosis (MS) disease management at the 2014 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), being held May 28–31 in Dallas, Texas. Demonstrations of MoveOverMS.org and the MS self™ multiple sclerosis app will be held in the MoveOverMS.org booth (#406) in the meeting exhibit hall.

MoverOverMS.org offers a multitude of tools to help those living with MS, including videos, articles and downloadable information. The MS self mobile app features informative fact cards, achievement badges, and an interactive journal that allows users to log moods, thoughts and activities. The app has recently been updated on the iTunes app store with new features and is free to download.

“We developed MoveOverMS.org and MS self to help people proactively manage the challenges they face living with MS. We are excited to share these digital tools with the healthcare professionals attending the CMSC/ACTRIMS meeting, providing them with additional resources for their patients,” said Adrian Rabinowicz, Acorda’s Senior Vice President, Clinical Development and Medical Affairs. “Our company’s mission is to improve the lives of people with neurological disorders. Research and development of novel medicines is a core component of our mission, as is providing support to people with MS, their care partners and healthcare team.”

About CMSC

The Consortium of Multiple Sclerosis Centers (CMSC) is the leading educational, training, and networking organization for MS healthcare professionals and researchers. The CMSC’s mission is to promote quality multiple sclerosis care through educational programming and accreditation, including live and online events, research grants, technical journals and papers, and targeted advocacy efforts. The CMSC member network includes more than 7,000 international healthcare clinicians and scientists committed to multiple sclerosis care as well as more than 60 Veterans Administration MS Programs and 225 MS Centers in the U.S., Canada, and Europe.

About ACTRIMS

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) provides leadership in the field of multiple sclerosis and other demyelinating diseases. MS clinicians and researchers founded ACTRIMS to serve as the U.S. and Canadian counterpart to ECTRIMS, the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS). The annual ACTRIMS meeting provides a forum to exchange information, debate current issues, and discuss advances related to basic and clinical issues in MS research.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies including: AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure. For more information, please visit the Company’s website at: www.acorda.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including Plumiaz (our trade name for Diazepam Nasal Spray), or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Plumiaz or other products under development; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen Idec in connection therewith; competition, including the impact of generic competition on Zanaflex Capsules revenues; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; failure to comply with regulatory requirements could result in adverse action by regulatory agencies; and the ability to obtain additional financing to support our operations. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities & Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.

Contacts

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com

Sharing

Contacts

Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com